Rafferty Asset Management’s Oruka Therapeutics ORKA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.82M Buy
69,824
+26,714
+62% +$2.52M 0.02% 351
2026
Q2
$4.1M Buy
43,110
+2,623
+6% +$175K 0.01% 406
2026
Q1
$1.99M Buy
40,487
+2,002
+5% +$69.6K 0.01% 612
2025
Q4
$1.17M Buy
38,485
+25,698
+201% +$716K ﹤0.01% 765
2025
Q3
$246K Buy
+12,787
New +$190K ﹤0.01% 1030

Other funds holding ORKA

Rafferty Asset Management's ORKA Position: Q3 2026 in Review

Rafferty Asset Management increased its Oruka Therapeutics (ORKA) stake by 62% in Q3 2026, buying an estimated $2.52M and bringing the position to 69,824 shares worth $5.82M. The position accounts for 0.02% of the portfolio, ranked #351.

Rafferty Asset Management first reported a position in ORKA in Q3 2025 and has held it in 5 quarters since. 175 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

  • Rafferty Asset Management held 69,824 shares of Oruka Therapeutics worth $5.82M as of Q3 2026.
  • Rafferty Asset Management bought 26,714 Oruka Therapeutics shares in Q3 2026, an estimated $2.52M.
  • Oruka Therapeutics made up 0.02% of Rafferty Asset Management's portfolio in Q3 2026, its #351 holding.
  • Rafferty Asset Management first reported a position in Oruka Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 175 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.